SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) today announced updates to its SurePrint miRNA Microarrays to include targets from the latest public miRNA miRBase database. The database, miRBase 21, contains 28,645 entries, including more than 15 percent in content added from miRBase 20.
Agilent SurePrint miRNA Microarrays feature innovative labeling and hairpin probe designs to provide exceptional sequence and size discrimination.
MicroRNA, or miRNA, research has grown dramatically in the effort to better understand gene regulation in diseases, such as cancer. The availability of Agilent SurePrint human, mouse and rat miRNA microarrays, with miRBase 21 targets, provides pre-designed microarrays for the most commonly studied models. Any species in the miRBase database can also be used to create a custom microarray through the Web-based design tool eArray to include probe content from the latest miRBase 21.
In a recently published miRQC study1, Agilent SurePrint miRNA Microarrays were compared with various qPCR, next-generation sequencing, and microarray platforms to benchmark performance. Starting with only 100 ng of total RNA, Agilent miRNA microarrays exhibited excellent performance with the highest titration response, reproducibility and precision in accuracy while requiring the lowest sample amount among the next-closest performing assays.
“Providing the latest content, easy customizability and superior performance in our miRNA microarrays reinforces the merits of our SurePrint technology,” said Alessandro Borsatti, senior director of Marketing for Agilent’s Diagnostics and Genomics group. “We maintain our commitment to microarrays because they provide well-proven and established workflows for scientists seeking the greatest efficiency and cost-effectiveness for investigating miRNAs.”
SurePrint miRNA Microarrays are part of the SurePrint product family, including gene expression and comparative genomic hybridization (CGH) microarrays. The breadth of microarray applications is enhanced by the depth of Agilent’s genomic workflow—from the 2100 Bioanalyzer and 2200 TapeStation for QC, to SureScan Scanner for data acquisition, GeneSpring for data analysis and AriaMX system for Real-Time PCR—to provide researchers a complete solution.
To learn more about SurePrint miRNA Microarrays, visit: www.agilent.com/genomics/miRNA21.
About Agilent in Genomics
Agilent is a global leader in target enrichment for next-generation sequencing and genomic microarrays. The Agilent SureSelect and HaloPlex target-enrichment systems enable researchers to easily choose which segments of a genome to sequence, avoiding the time and expense needed to sequence the entire genome. HaloPlex offers a same-day sample-to-sequencer workflow; SureSelect can accurately capture whole exomes and whole methylomes in a single reaction. These are just two products arising from Agilent’s expertise in synthesizing custom complex mixtures of long oligonucleotides gained in microarray manufacturing. Additional product lines built on this core technology include microarrays for genome-wide measurement of gene expression and for comparative genomics hybridization, as well as SureFISH, a highly specific and sensitive product line for oligonucleotide fluorescent in situ hybridization. In addition to oligonucleotide-based products, Agilent offers a microfluidic bioanalyzer to measure sample quality, and a full set of reagents, hardware, methods and bioinformatics software for genomic experiments.
For more information on Agilent’s complete line of Genomics solutions, visit: www.chem.agilent.com/en-US/Solutions/Genomics/Pages/default.aspx.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A) is a leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.
This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the separation of Agilent’s electronic measurement business; future revenues, earnings and profitability; the future demand for the company’s products and services; and customer expectations. These forward-looking statements involve risks and uncertainties that could cause Agilent’s results to differ materially from management’s current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers’ businesses; unforeseen changes in the demand for current and new products, technologies, and services; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities.
In addition, other risks that Agilent faces include those detailed in Agilent’s filings with the Securities and Exchange Commission, including our latest Form 10-K and Form 10-Q. Forward-looking statements are based on the beliefs and assumptions of Agilent’s management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.
1 P. Mestdagh et al., Nature Methods 11, 809–815 (2014)
NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.